#USA #Abbott #Northridge #diabetes #MiniMed

MiniMed and Abbott Join Forces for Innovative Diabetes Monitoring

In a significant development in diabetes technology, MiniMed (NASDAQ: MMED) has announced an expansion of its collaboration with Abbott to introduce integrated dual glucose-ketone sensors tailored specifically for MiniMed smart dosing systems. This move is expected to enhance the management of diabetes and provide users with more efficient tools for their health.

Enhanced Features for Better Management

The new sensors are designed to offer early, real-time detection of ketone levels, which is crucial for preventing diabetic ketoacidosis (DKA), a potentially life-threatening condition. By integrating these sensors into MiniMed’s existing systems, the companies aim to provide users with additional layers of safety and intelligence in their diabetes management.

Que Dallara, the CEO of MiniMed, emphasized the importance of this partnership, stating that the integration will not only keep users in tighter glucose control but will also minimize the risk of DKA through smarter, more consistent automation. The goal is to intervene before emergencies arise, thereby offering individuals living with diabetes greater peace of mind.

The Importance of Monitoring Ketones

Diabetic ketoacidosis is a serious complication that can lead to numerous hospitalizations each year, particularly among individuals with type 1 diabetes. Unfortunately, traditional methods of ketone monitoring, which often involve separate finger-stick tests or urine strips, can delay urgent care, as they are typically performed only after symptoms appear. This new integrated approach aims to change that by providing continuous ketone data directly to MiniMed's insulin delivery system, allowing for quicker interventions.

Key Attributes of the New Sensors

The dual glucose-ketone monitoring sensors will have the same compact size as Abbott's Instinct sensor, which is recognized for being the smallest and thinnest sensor available. This sleek design ensures that users can manage their diabetes without the inconvenience of bulky devices.

Availability and Future Developments

While the dual glucose-ketone systems are not yet available for sale in the United States, Abbott has recently received a CE Mark for its dual glucose-ketone system and continues its review process with the FDA. Updates regarding regulatory and commercialization milestones are expected in the coming months, promising exciting advancements for those living with diabetes.

Conclusion

The collaboration between MiniMed and Abbott represents a monumental step forward in diabetes care technology. By enabling more proactive management strategies through continuous monitoring, these integrated sensors could potentially revolutionize how individuals with diabetes approach their condition. As both companies work towards bringing this technology to market, the anticipation grows for the enhanced safety and control it will provide.

For more information on the collaboration and future products, stay tuned for upcoming announcements from both MiniMed and Abbott.